Does Flecainide Cause Cancer?
No, flecainide does not directly cause cancer, but there is emerging evidence suggesting an association with increased risk of skin cancers (both melanoma and non-melanoma skin cancer), though the mechanism remains unclear and may involve confounding factors rather than direct carcinogenicity.
Evidence from Drug Safety Data
The FDA-approved drug label for flecainide does not list cancer or skin cancer as a known adverse effect 1. Long-term carcinogenicity studies in rats and mice at doses up to 60 mg/kg/day revealed no compound-related carcinogenic effects, and mutagenicity studies (Ames test, mouse lymphoma, and in vivo cytogenetics) showed no mutagenic effects 1.
Emerging Epidemiological Evidence
However, a large 2022 nested case-control study across Spain and Denmark found concerning associations 2:
- Melanoma risk (Denmark only): High-use of flecainide (cumulative dose ≥200g) showed an adjusted OR of 1.97 (95% CI 1.38-2.81) compared to never-use
- Non-melanoma skin cancer (NMSC):
- Denmark: OR 1.34 (95% CI 1.15-1.56)
- Spain (BIFAP): OR 1.42 (95% CI 1.04-1.93)
- Spain (SIDIAP): OR 1.19 (95% CI 0.95-1.48)
Critical limitation: The study found no substantial dose-response pattern, which weakens the argument for direct causation and suggests potential unmeasured confounders (such as UV exposure, genetic factors, or other medications).
Clinical Guidelines Do Not Address Cancer Risk
Major cardiovascular guidelines from the Canadian Cardiovascular Society 3, 4, 3, American College of Cardiology/American Heart Association 5, 6, and other societies 7, 4, 8 extensively discuss flecainide's cardiovascular risks (proarrhythmia, negative inotropy, conduction abnormalities) but make no mention of cancer risk. This absence from guidelines reflects that cancer is not an established or clinically significant concern in routine practice.
Known Adverse Effects of Flecainide
The established risks that should guide clinical decision-making include 3, 1:
- Proarrhythmia: Increased mortality in patients with structural heart disease (CAST trial)
- Contraindications:
- Ischemic heart disease or history of MI
- LV systolic dysfunction (LVEF <40%)
- Advanced AV block
- Severe renal impairment (CrCl <35 mL/min)
- Common side effects: Dizziness (18.9%), visual disturbances (15.9%), dyspnea (10.3%)
Practical Clinical Approach
For patients currently on or being considered for flecainide:
Do not discontinue flecainide based solely on skin cancer concerns - the cardiovascular benefits in appropriate patients (those without structural heart disease requiring rhythm control) outweigh the uncertain and modest skin cancer risk
Implement enhanced dermatologic surveillance if flecainide is necessary:
- Annual full-body skin examination by dermatologist
- Patient education on self-skin examination
- Sun protection counseling (broad-spectrum sunscreen, protective clothing, avoiding midday sun 10 AM-4 PM) 9
Consider alternative antiarrhythmics in patients with:
- Personal history of melanoma or multiple NMSCs
- Strong family history of melanoma
- Fair skin with extensive sun damage
- Other photosensitizing medications
Document the discussion about potential skin cancer association when prescribing flecainide, acknowledging the uncertain nature of this risk
Important Caveats
The skin cancer association may reflect confounding by indication rather than direct drug effect - patients with atrial fibrillation requiring flecainide may have different baseline cancer risks, sun exposure patterns, or concurrent medications (other photosensitizing drugs) that explain the observed association 2. The lack of dose-response relationship and absence of biological plausibility (negative carcinogenicity studies) support this interpretation.
The established cardiovascular risks of flecainide remain far more clinically significant than the uncertain skin cancer association and should drive prescribing decisions.